Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17190382 | 0.98 | GAA (0.33) | ATMGAAEPHX1CYP19A1NPC1 | |
| SCHEMBL17079962 | 0.95 | NFKB1 (0.30) | — | |
| SCHEMBL29919514 | 0.95 | NFKB1 (0.30) | — | |
| SCHEMBL7102620 | 0.88 | MAPT (0.32) | — | |
| SCHEMBL17190371 | 0.82 | GAA (0.32) | GAAEPHX1 | |
| SCHEMBL3677465 | 0.81 | MAPT (0.35) | EPHX1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17190445 | 0.81 | CHRM2 (0.33) | — | |
| SCHEMBL17301551 | 0.81 | — | — | |
| SCHEMBL17190358 | 0.81 | EPHX1 (0.33) | GAAEPHX1 | |
| SCHEMBL17190443 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10450282-B2 | Stereospecific process for 3-heterocyclylcycloaliphatic-1,2-diols | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2019-10-22 | — | — | US | disclosed |
| EP-3331867-A1 | STEREOSPECIFIC PROCESS FOR 3-HETEROCYCLYLCYCLOALIPHATIC-1,2-DIOLS | Icahn School of Medicine at Mount Sinai (US) | 2018-06-13 | — | — | EP | disclosed |
| WO-2017024229-A1 | STEREOSPECIFIC PROCESS FOR 3-HETEROCYCLYLCYCLOALIPHATIC-1,2-DIOLS | ICAHN SCHOOL OF MEDECINE AT MOUNT SINAI (US) | 2017-02-09 | — | — | WO | disclosed |
| WO-2017024229-A1 | STEREOSPECIFIC PROCESS FOR 3-HETEROCYCLYLCYCLOALIPHATIC-1,2-DIOLS | ICAHN SCHOOL OF MEDECINE AT MOUNT SINAI (US) | 2017-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10450282-B2 | Stereospecific process for 3-heterocyclylcycloaliphatic-1,2-diols | DDT, ODC1, CBR1 | ATM 4670/4885GAA 3750/4885EPHX1 1281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.